Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

7.4K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

697
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
697
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

313
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
313
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.4K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of RNA-binding proteins affinity to export receptors enables the nuclear basket proteins to distinguish and retain aberrant mRNAs.

Scientific reports·2016
Same author

Rapid Brownian Motion Primes Ultrafast Reconstruction of Intrinsically Disordered Phe-Gly Repeats Inside the Nuclear Pore Complex.

Scientific reports·2016
Same author

Evolutionarily Conserved Sequence Features Regulate the Formation of the FG Network at the Center of the Nuclear Pore Complex.

Scientific reports·2015
Same author

The value of non-human primates in the development of monoclonal antibodies.

Nature biotechnology·2013
Same author

The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies.

Regulatory toxicology and pharmacology : RTP·2013
Same author

The cost-effectiveness of periodic safety update reports for biologicals in Europe.

Clinical pharmacology and therapeutics·2013

Related Experiment Video

Updated: Mar 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Interferon Beta: From Molecular Level to Therapeutic Effects.

M Haji Abdolvahab1, M R K Mofrad2, H Schellekens1

  • 1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands.

International Review of Cell and Molecular Biology
|August 31, 2016
PubMed
Summary

Interferon beta (IFNβ), a vital cytokine for treating diseases like multiple sclerosis, can trigger antidrug antibodies. Understanding its structure is key to developing safer, more effective IFNβ therapies.

Keywords:
antibodiesepitopesimmunogenicityinterferon betamolecular aggregatesmultiple sclerosis

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.4K

Related Experiment Videos

Last Updated: Mar 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.4K

Area of Science:

  • Immunology
  • Biochemistry
  • Pharmacology

Background:

  • Interferon beta (IFNβ) is a naturally occurring cytokine with antiviral, antiproliferative, and immunomodulatory functions.
  • It signals through the type I IFN receptor (IFNAR1/IFNAR2) and regulates gene expression via JAK/STAT pathways.
  • IFNβ is therapeutically used for conditions like hepatitis C and multiple sclerosis.

Purpose of the Study:

  • To review current knowledge on Interferon beta (IFNβ).
  • To discuss IFNβ's structure, dynamics, signaling, mechanism of action, and therapeutic effects.
  • To explore the relationship between IFNβ's structural properties and its immunogenicity.

Main Methods:

  • Literature review of Interferon beta (IFNβ) research.
  • Analysis of IFNβ's structural properties, including aggregation and epitopes.
  • Examination of methods used to predict and reduce IFNβ immunogenicity.

Main Results:

  • IFNβ exhibits pleiotropic activities, making it effective against various diseases.
  • Antidrug antibodies can arise during IFNβ therapy, potentially reducing efficacy.
  • Structural factors like aggregation and epitopes are critical determinants of IFNβ immunogenicity.

Conclusions:

  • Knowledge of IFNβ structure and dynamics is crucial for understanding its therapeutic effects and immunogenicity.
  • Addressing structural properties can lead to the development of safer and more effective IFNβ drug products.
  • Further research into IFNβ immunogenicity is needed to optimize therapeutic strategies.